Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic wistar rats

Tomokazu Shinozaki, Masaki Kimura, Makoto Hosoyamada, Toshiaki Shibasaki

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The effects of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), were studied in normophagic and food-restriction-induced hyperphagic middle-aged Wistar rats. Normophagic intact Wistar rats were given fluvoxamine (100 mg/kg/d, per os (p.o.)) or vehicle for 10 d. Hyperphagic middle-aged Wistar rats were subjected to 10 d of food restriction; they were allowed to refeed for 10 d, with ad libitum food access and administered fluvoxamine (100 mg/kg/d, p.o.) or vehicle during the 10-d refeeding period. Fluvoxamine administration to normophagic middle-aged Wistar rats affected neither their weight nor food intake. However, administration to food-restricted rats showed inhibitory effects of weight gain and food intake during 10 d of refeeding. Fluvoxamine-treated rats showed significantly lower neuropeptide Y (NPY) immunostaining levels in the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus (DMH) than untreated controls. Hypophagic and weight-inhibiting effects of fluvoxamine might be mediated via decreased NPY in PVN and DMH. These results suggest that the appetite-controlling effect of fluvoxamine might be responsive to the rats' appetite condition.

Original languageEnglish
Pages (from-to)2250-2254
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Volume31
Issue number12
DOIs
Publication statusPublished - 2008

Fingerprint

Fluvoxamine
Weight Gain
Wistar Rats
Eating
Food
Dorsomedial Hypothalamic Nucleus
Paraventricular Hypothalamic Nucleus
Neuropeptide Y
Appetite
Weights and Measures
Serotonin Uptake Inhibitors

Keywords

  • 5-hydroxytryptamine
  • Appetite condition
  • Fluvoxamine
  • Neuropeptide y
  • Obesity

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic wistar rats. / Shinozaki, Tomokazu; Kimura, Masaki; Hosoyamada, Makoto; Shibasaki, Toshiaki.

In: Biological and Pharmaceutical Bulletin, Vol. 31, No. 12, 2008, p. 2250-2254.

Research output: Contribution to journalArticle

Shinozaki, Tomokazu ; Kimura, Masaki ; Hosoyamada, Makoto ; Shibasaki, Toshiaki. / Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic wistar rats. In: Biological and Pharmaceutical Bulletin. 2008 ; Vol. 31, No. 12. pp. 2250-2254.
@article{a0d2db1ee11d468e8eb38dc9a7441d44,
title = "Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic wistar rats",
abstract = "The effects of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), were studied in normophagic and food-restriction-induced hyperphagic middle-aged Wistar rats. Normophagic intact Wistar rats were given fluvoxamine (100 mg/kg/d, per os (p.o.)) or vehicle for 10 d. Hyperphagic middle-aged Wistar rats were subjected to 10 d of food restriction; they were allowed to refeed for 10 d, with ad libitum food access and administered fluvoxamine (100 mg/kg/d, p.o.) or vehicle during the 10-d refeeding period. Fluvoxamine administration to normophagic middle-aged Wistar rats affected neither their weight nor food intake. However, administration to food-restricted rats showed inhibitory effects of weight gain and food intake during 10 d of refeeding. Fluvoxamine-treated rats showed significantly lower neuropeptide Y (NPY) immunostaining levels in the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus (DMH) than untreated controls. Hypophagic and weight-inhibiting effects of fluvoxamine might be mediated via decreased NPY in PVN and DMH. These results suggest that the appetite-controlling effect of fluvoxamine might be responsive to the rats' appetite condition.",
keywords = "5-hydroxytryptamine, Appetite condition, Fluvoxamine, Neuropeptide y, Obesity",
author = "Tomokazu Shinozaki and Masaki Kimura and Makoto Hosoyamada and Toshiaki Shibasaki",
year = "2008",
doi = "10.1248/bpb.31.2250",
language = "English",
volume = "31",
pages = "2250--2254",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "12",

}

TY - JOUR

T1 - Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic wistar rats

AU - Shinozaki, Tomokazu

AU - Kimura, Masaki

AU - Hosoyamada, Makoto

AU - Shibasaki, Toshiaki

PY - 2008

Y1 - 2008

N2 - The effects of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), were studied in normophagic and food-restriction-induced hyperphagic middle-aged Wistar rats. Normophagic intact Wistar rats were given fluvoxamine (100 mg/kg/d, per os (p.o.)) or vehicle for 10 d. Hyperphagic middle-aged Wistar rats were subjected to 10 d of food restriction; they were allowed to refeed for 10 d, with ad libitum food access and administered fluvoxamine (100 mg/kg/d, p.o.) or vehicle during the 10-d refeeding period. Fluvoxamine administration to normophagic middle-aged Wistar rats affected neither their weight nor food intake. However, administration to food-restricted rats showed inhibitory effects of weight gain and food intake during 10 d of refeeding. Fluvoxamine-treated rats showed significantly lower neuropeptide Y (NPY) immunostaining levels in the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus (DMH) than untreated controls. Hypophagic and weight-inhibiting effects of fluvoxamine might be mediated via decreased NPY in PVN and DMH. These results suggest that the appetite-controlling effect of fluvoxamine might be responsive to the rats' appetite condition.

AB - The effects of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), were studied in normophagic and food-restriction-induced hyperphagic middle-aged Wistar rats. Normophagic intact Wistar rats were given fluvoxamine (100 mg/kg/d, per os (p.o.)) or vehicle for 10 d. Hyperphagic middle-aged Wistar rats were subjected to 10 d of food restriction; they were allowed to refeed for 10 d, with ad libitum food access and administered fluvoxamine (100 mg/kg/d, p.o.) or vehicle during the 10-d refeeding period. Fluvoxamine administration to normophagic middle-aged Wistar rats affected neither their weight nor food intake. However, administration to food-restricted rats showed inhibitory effects of weight gain and food intake during 10 d of refeeding. Fluvoxamine-treated rats showed significantly lower neuropeptide Y (NPY) immunostaining levels in the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus (DMH) than untreated controls. Hypophagic and weight-inhibiting effects of fluvoxamine might be mediated via decreased NPY in PVN and DMH. These results suggest that the appetite-controlling effect of fluvoxamine might be responsive to the rats' appetite condition.

KW - 5-hydroxytryptamine

KW - Appetite condition

KW - Fluvoxamine

KW - Neuropeptide y

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=57349133071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349133071&partnerID=8YFLogxK

U2 - 10.1248/bpb.31.2250

DO - 10.1248/bpb.31.2250

M3 - Article

C2 - 19043208

AN - SCOPUS:57349133071

VL - 31

SP - 2250

EP - 2254

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 12

ER -